Passage Bio Inc (NAS:PASG)
$ 0.7925 -0.0075 (-0.94%) Market Cap: 49.41 Mil Enterprise Value: -11.14 Mil PE Ratio: 0 PB Ratio: 0.68 GF Score: 37/100

Passage Bio Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 11, 2020 / 03:20PM GMT
Release Date Price: $23.09 (-7.64%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Good morning. Thanks for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and we're pleased to have Passage Bio with us. We have Bruce Goldsmith, Chief Executive Officer; and Richard Morris, Chief Financial Officer.

Questions & Answers

Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

And with that, given Passage just completed its IPO in February, could you please walk us through the Passage story and where it stands?

Bruce A. Goldsmith
Passage Bio, Inc. - CEO, President & Director

Yes, Salveen, thanks for the opportunity to participate in the conference, and thanks for hosting us.

So the way we view Passage Bio is that we are positioned to become the premier genetic medicines company. And it's really based on what we see as a differentiated approach developing treatments for rare monogenic CNS disorders and an extremely deep pipeline that we've built through an

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot